SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla rises as its arm acquires 26% stake in AMPIN Energy C&I Eighteen

30 May 2025 Evaluate

Cipla is currently trading at Rs. 1487.25, up by 10.70 points or 0.72% from its previous closing of Rs. 1476.55 on the BSE.

The scrip opened at Rs. 1484.40 and has touched a high and low of Rs. 1488.90 and Rs. 1472.10 respectively. So far 18289 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1702.00 on 09-Oct-2024 and a 52 week low of Rs. 1310.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1493.70 and Rs. 1463.10 respectively. The current market cap of the company is Rs. 120216.63 crore.

The promoters holding in the company stood at 29.20%, while Institutions and Non-Institutions held 54.42% and 16.38% respectively.

Cipla’s subsidiary -- Jay Precision Pharmaceuticals has completed acquisition of 26% stake in AMPIN Energy C&I Eighteen on May 28, 2025. This is in line with the commitment to enhance the share of renewable power source in its operation and to comply with regulatory requirement for being a ‘captive user’ under Indian electricity laws.

Earlier, Jay Precision Pharmaceuticals had entered into Share Purchase, Subscription and Shareholder’s Agreement (SPSSA) to acquire 26% stake on a fully diluted basis in AMPIN Energy C&I Eighteen, for setting up captive solar power project in Maharashtra.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1288.00 -17.85 (-1.37%)
24-Apr-2026 11:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1622.45
Dr. Reddys Lab 1316.50
Cipla 1288.00
Zydus Lifesciences 932.20
Lupin 2281.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×